Compare Arqit Quantum Inc (ARQQ) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arqit Quantum Inc vs Moderna, Inc. — how do they compare? Arqit Quantum Inc trades at $18.15 (market cap $332.04M), while Moderna, Inc. trades at $68.82 (market cap $27.09B). The key difference: Moderna, Inc. is far larger — about 81.6× Arqit Quantum Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Arqit Quantum Inc nearer its low. Which is the better fit depends on your goals.
| ARQQ | MRNA | |
|---|---|---|
Market Cap | $332.04M | $27.09B |
Sector | Technology | Health |
52-Week High | $58.27 | $81.80 |
52-Week Low | $11.78 | $22.36 |
Enterprise Value | $305.35M | $23.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARQQ trades at $19.08, down 6.79% today, with a bearish technical signal from moving averages. The company reported $530K revenue for 2025 but a net loss of $35.34M, with negative profit margins and high valuation ratios. Recent news highlights contract wins and 829% YoY revenue growth in H1 FY26, though earnings misses persist.
Outlook remains speculative given deep losses and high P/S of 275.84, but growth in quantum security deals offers potential. Key risks include cash burn and competitive threats. Analyst consensus is split 50/50 buy/hold, indicating cautious optimism amid fundamental challenges.
Moderna (MRNA) trades at $68.27, down 10.83% amid a biotech sell-off, but maintains a bullish technical trend with strong moving averages. Revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B, yet recent quarterly EPS beats and pipeline expansions into oncology and flu vaccines fuel optimism. The stock remains volatile, with a consensus price target of $49.00 below the current price, reflecting mixed analyst sentiment.
The outlook hinges on pipeline execution, with EU RSV vaccine contracts and FDA decisions offering upside, but high cash burn and competitive pressures pose risks. Investors face a trade-off between growth potential and profitability challenges, with the stock's 70% monthly surge testing sustainability near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Arqit Quantum Inc
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
